Get the Stockscreener App
0.98
5.16%
0.0481
After Hours:
.97
-0.01
-1.02%
Hoth Therapeutics Inc stock is traded at $0.98, with a volume of 905.61K.
It is up +5.16% in the last 24 hours and down -7.55% over the past month.
Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).
See More
Previous Close:
$0.9319
Open:
$0.93
24h Volume:
905.61K
Relative Volume:
2.18
Market Cap:
$15.20M
Revenue:
-
Net Income/Loss:
$-7.51M
P/E Ratio:
-0.7424
EPS:
-1.32
Net Cash Flow:
$-8.02M
1W Performance:
+27.26%
1M Performance:
-7.55%
6M Performance:
-22.83%
1Y Performance:
-9.26%
1-Day Range:
$0.905
$1.01
1-Week Range:
$0.7704
$1.01
52-Week Range:
$0.6554
$2.115
Hoth Therapeutics Inc Stock (HOTH) Company Profile
Name
Hoth Therapeutics Inc
Sector
Industry
Phone
(646)756-2997
Address
1177 AVENUE OF THE AMERICAS, NEW YORK, NY
Compare HOTH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOTH
Hoth Therapeutics Inc
|
0.98 | 14.46M | 0 | -7.51M | -8.02M | -1.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Hoth Therapeutics Inc Stock (HOTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-19 | Initiated | The Benchmark Company | Speculative Buy |
Hoth Therapeutics Inc Stock (HOTH) Latest News
Hoth Therapeutics receives U.S. notice of allowance for novel exon-skipping therapy targeting allergic diseases - marketscreener.com
Hoth Therapeutics Receives U.S. Notice Of Allowance For Novel Exon-Skipping Therapy Targeting Allergic Diseases - TradingView
Hoth Therapeutics Receives U.S. Notice of Allowance for Novel Exon-Skipping Therapy Targeting Allergic Diseases - PR Newswire
Why Hoth Therapeutics Inc. stock is a must watch in 2025Trade Volume Summary & Pattern Based Trade Signal System - mfd.ru
Hoth Therapeutics' GDNF Study Outperforms Semaglutide in Key Metrics - Intellectia AI
Hoth Therapeutics announces groundbreaking positive results: HT-VA GDNF surpasses Semaglutide in weight loss - marketscreener.com
Hoth Therapeutics' GDNF Therapy Shows Breakthrough Efficacy in Obesity Treatment - Intellectia AI
Hoth Therapeutics' GDNF Treatment Shows Superior Efficacy Over Wegovy, Ozempic In Preclinical Trial - Stocktwits
Hoth’s obesity treatment outperforms semaglutide in preclinical study - Investing.com
Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model - PR Newswire
EXCLUSIVE: Small Biotech Hoth Therapeutics Claims Experimental Obesity Drug Topped Famed Wegovy In Preclinical Study - Benzinga
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing HT-001 Oncology Trial Toward Multi-Country Site Activation - Eastern Progress
Travel Stocks: What is CROXs TAM Total Addressable MarketJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
Is Hoth Therapeutics Inc stock trending bullishTrade Volume Summary & Intraday High Probability Setup Alerts - baoquankhu1.vn
Hoth Therapeutics Addresses Market Rumor, Hoth Holds No Crypto Currency Assets - marketscreener.com
Hoth Therapeutics (HOTH) Price Target Increased by 11.11% to 5.10 - Nasdaq
Aug Final Week: Can KVACW outperform in the next rallyTrade Analysis Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Hoth Therapeutics stock rises after filing patents for cancer therapy skin toxicity treatments - Investing.com Nigeria
Risk Analysis: Can BSVN expand into new marketsMarket Activity Report & Verified Stock Trade Ideas - baoquankhu1.vn
Market Leaders: What are analysts price targets for HOVRWJuly 2025 Volume & Safe Capital Growth Stock Tips - baoquankhu1.vn
Pharma News: What are the risks of holding Aduro Clean Technologies IncMarket Weekly Review & AI Forecast Swing Trade Picks - baoquankhu1.vn
Bear Alert: Can National Energy Services Reunited Corp Equity Warrant keep up with sector leaders2025 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Hoth Therapeutics gains after winning China patent for HT-KIT cancer program - MSN
Hoth reports positive interim results for cancer skin therapy By Investing.com - Investing.com Nigeria
Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half - Benzinga
Hoth Therapeutics stock rises after positive interim trial results By Investing.com - Investing.com South Africa
Hoth Therapeutics stock rises after positive interim trial results - Investing.com
Hoth reports positive interim results for cancer skin therapy - Investing.com
Cancer patients on EGFR drugs report less toxicity and itch with HT-001 - stocktitan.net
Hoth Therapeutics secures Chinese patent for cancer cell therapy By Investing.com - Investing.com Nigeria
Sell Signal: What’s the outlook for Hoth Therapeutics Inc.’s sector2025 Price Action Summary & Expert Verified Movement Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Hoth Therapeutics stock rises after securing Chinese patent for cancer therapy By Investing.com - Investing.com Australia
Hoth Therapeutics stock rises after securing Chinese patent for cancer therapy - Investing.com Nigeria
Hoth Therapeutics secures Chinese patent for cancer cell therapy - Investing.com
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position - PR Newswire
Aug Analyst Calls: Can Salarius Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Patterns & High Conviction Investment Ideas - baoquankhu1.vn
Why Hoth Therapeutics Inc. stock could outperform in 2025July 2025 Review & Low Drawdown Investment Strategies - bollywoodhelpline.com
3 Under-the-Radar Biotechs Under $5 That Could Soar 200% - MSN
Hoth Therapeutics highlights obesity and pipeline progress to regulators - TipRanks
Hoth Therapeutics, Inc. Presents New Drug Development Initiatives - TradingView — Track All Markets
Hoth Therapeutics receives positive EU regulatory decision for cancer trial By Investing.com - Investing.com Nigeria
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Cancer trial to test topical drug for skin side effects from therapy - Stock Titan
Hoth Therapeutics receives positive EU regulatory decision for cancer trial - Investing.com
Hoth Therapeutics Reaches Key EU Regulatory Inflection Point Advancing Ht-001 Oncology Trial Toward Multi-Country Site Activation - TradingView
Hoth Therapeutics Inc Stock (HOTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):